SPA
TRDA icon

Sherbrooke Park Advisers’s Entrada Therapeutics TRDA Stock Holding History

Sherbrooke Park Advisers’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,573
Closed -$108K – 521
2025
Q3 		$108K Buy
+18,573
New +$109K 0.05% 444
2024
Q4 		– Sell
-11,553
Closed -$185K – 1163
2024
Q3 		$185K Buy
+11,553
New +$182K 0.04% 770

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sherbrooke Park Advisers's TRDA Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of Entrada Therapeutics (TRDA) in Q4 2025, closing a stake of 18,573 shares — an estimated $108K sold.

Sherbrooke Park Advisers first reported a position in TRDA in Q3 2024 and held it in 2 quarters. The position peaked at $185K in Q3 2024. 114 funds tracked by Wall St. Rank hold TRDA as of Q4 2025.

  • Sherbrooke Park Advisers reported no remaining Entrada Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 18,573 Entrada Therapeutics shares in Q4 2025, an estimated $108K.
  • Sherbrooke Park Advisers first reported a position in Entrada Therapeutics in Q3 2024 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Entrada Therapeutics position peaked at $185K in Q3 2024.
  • 114 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.